Transparency Market Research Glioblastoma Multiforme Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
Published Date 2015-06-10
101 Page Report
Buy Now
Request Sample
Press Release
Pipeline Review of Glioblastoma Treatment Market Expected to Reach USD 0.91 Billion in 2022 Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Glioblastoma Multiforme Treatment Market
REPORT DESCRIPTION
Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 According to a new market report published by Transparency Market Research “ Pipeline Review of Glioblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022,� the global glioblastoma treatment market was valued at USD 0.34 billion in 2013 and is estimated to reach USD 0.91 billion by 2022 at a CAGR of 11.4% from 2014 to 2022. Glioblastoma multiforme (GBM) is a rapid-growing and most invasive form of glioma that develops from star-shaped glial cells (astrocytes and oliodedrocytes) that support health of the nerve cells within the brain. The treatment options available for GBM are surgeries, radiation therapy, chemotherapy and stereotactic radiosurgery. The primary objective of a surgery is to remove as much of the tumor as possible without injuring the surrounding normal brain tissues required for normal neurological functions. However, aggressive invasion, migration, and infiltration of tumor cells in healthy cells makes it impossible to remove the tumor completely from the sight. Hence, chemotherapy is used to shrink the tumor or as a post-surgery treatment to irradiate remaining cancer cells. Radiation therapy also helps to control the growth of the tumor and may be used instead of or in addition to the surgery. According to the experts, chemotherapy and radiation therapy helps to extend the overall survival period of GBM patient to approximately one year. Thus, the treatments such as temozolomide, carmustine and bevacizumab are most effective against GBM than any other available treatments.
Browse the full Glioblastoma Multiforme Treatment Market Report @ : http://www.transparencymarketresearch.com/pipeline-review-of-glioblastomatreatment-market.html Carmustine drug is brand named as Gliadel (Arbor Pharmaceuticals, LLC) which is a surgical implant, while bevacozumab (Brand name Avastin, product of Genetech/ Roche) is targeted for intravenous therapy and temozolomide (Temodar/ Temodal/ Temcad and other brands) is recommended for intravenous or oral chemotherapy. Temozolomide, (TMZ) (brand names Temodar/ Temodal/ Temcad) is an alkylating agent used for the treatment of Grade IV astrocytoma (GBM). It is the most preferred treatment combined with surgery or radiotherapy that accounted for the highest market share in GBM treatment market. Temozolomide lost its
Transparency Market Research
2
Glioblastoma Multiforme Treatment Market
market share after losing its market exclusivity in 2012, which was later cannibalized by more efficient monoclonal antibody, bevacizumab (Avastin). Therefore, in the near future bevacizumab is expected to surpass the temozolomide revenues in GBM treatment market. As per the guidelines of National Institute for Health and Care Excellence (NICE), carmustine implants are recommended as a possible treatment for people with newly diagnosed high-grade glioma only if 90% or more of their tumor has been removed. Due to invasive applications carmustine compared to temozolomide and bevacizumab, carmustine accounts for the lowest market share in GBM treatment market.
Browse the full Glioblastoma Multiforme Treatment Market Press Release @ : http://www.transparencymarketresearch.com/pressrelease/global-glioblastomatreatment-industry.htm The phase III of GBM treatment pipeline comprises two most promising products of the future GBM market; namely Rindopepimut or CDX-110 (Celldex Therapeutics) and DCVax-L (Northwest Biotherapeutics). These two molecules have performed well in phase II clinical trials in terms of exceeding the overall survival period for patients. There are more than 50 drug candidates in phase I and phase II clinical trials including biologics, small molecules, devices, surgeries, and immunotherapy. The established companies of GBM market are F. Hoffman-La Roche, Arbor Pharmaceuticals, LLC and Merck & Co., while Celldex Therapeutics and Northwest Biotherapeutics are the new players that are expected to lead the GBM market. The pipeline review of glioblastoma treatment market has been segmented as below: Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs •
Bevacizumab (Avastin)
•
Temozolomide (Temodar and Temodal and Temcad)
•
Carmustine (BiCNU)
Global Glioblastoma Treatment Market Revenue and Forecast, by Geography •
North America
•
Europe
•
Asia Pacific
Transparency Market Research
3
Glioblastoma Multiforme Treatment Market
•
Rest of the World
Global Pipeline Review of Glioblastoma Treatment •
Overview
•
Late Stage (Phase III)
•
DCVax
•
Rindopepimut (CDX-110)
•
Others
Early Stage (Phase I, II and Pre clinical) •
ABT-414
•
MM-398
•
ARC-100
•
AV0113
•
Cotara
•
Crenolanib
•
SGT-53
•
Endostatin
•
ANG1005
•
Others
Get Free Sample Report : http://www.transparencymarketresearch.com/sample/sample.php? flag=s&rep_id=4807 TABLE OF CONTENT
Transparency Market Research
4
Glioblastoma Multiforme Treatment Market
Chapter 1 Preface 1.1 Report Description
Chapter 2 Executive Summary 2.1 Market Snapshot: Global Glioblastoma Multiforme Treatment Market (2014 and 2022) 2.2 Global Glioblastoma Multiforme Treatment Market, by Drug, 2013 (USD Million) 2.3 Comparative Analysis: Glioblastoma Multiforme Treatment Market, by Geography, 2013 and 2022 (Value %)
Chapter 3 Market Overview 3.1 Introduction and Market Definition 3.2 Disease Overview 3.2.1 Subtypes of Glioblastoma Multiforme 3.2.1.1 Signatures and Clinical features of GBM subtypes 3.2.2 Epidemiology 3.2.3 Standard treatment options and alternative therapeutics approaches 3.3 Nucleic Acid Delivery Methods 3.3.1 Virus-based 3.3.2 Nonviral-based
Transparency Market Research
5
Glioblastoma Multiforme Treatment Market
3.3.3 Stem cells 3.4 In Vivo Identification of GBM for Diagnostic Implication 3.4.1 Magnetic Resonance Imaging (MRI) 3.4.2 Computed Tomography (CT) 3.4.3 Positron Emission Tomography (PET) 3.4.4 Others 3.5 Biomolecule delivery systems 3.5.1 For Glioblastoma 3.5.1.1 Example of homing targets, polymeric coatings, nanoparticle configurations, and therapeutic agents utilized in nanoparticle drug delivery for glioma 3.5.2 For other Central Nervous System (CNS) disorders 3.6 Market Dynamics 3.6.1 Drivers 3.6.1.1 Rising geriatric population will drive the GBM treatment market as they are more prone to cause GBM 3.6.1.2 Global Rate of Aging Population 3.6.1.3 Various government and non-government organizations are creating worldwide awareness against GBM 3.6.1.4 The future of glioblastoma treatment market expects introduction of several novel therapies due to its strong pipeline 3.6.2 Restraints
Transparency Market Research
6
Glioblastoma Multiforme Treatment Market
3.6.2.1 GBM is highly resistant to DNA modifying agents hence available therapies have limitations 3.6.2.2 The overall survival period delivered by current FDA approved treatments is less 3.6.3 Opportunities 3.6.3.1 Development of immunotherapy and biological therapy treatments along with novel drug delivery systems add advantage over the current conventional treatments 3.7 Event Impact Analysis 3.8 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 – 2022 (USD Million) 3.8.1 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2012 – 2022 (USD Million) 3.8.2 Bevacizumab (Avastin) 3.8.2.1 Global Bevacizumab Market Revenue, 2012 - 2022 (USD Million) 3.8.3 Temozolomide 3.8.3.1 Global Temozolomide Market Revenue, 2012 - 2022 (USD Million) 3.8.4 Carmustine (BiCNU) 3.8.4.1 Global Carmustine (BiCNU) Market Revenue, 2012 - 2022 (USD Million) 3.9 Global Glioblastoma Treatment Market Revenue and Forecast, by Geography, 2012 – 2022 (USD Million) 3.9.1 North America
Transparency Market Research
7
Glioblastoma Multiforme Treatment Market
3.9.1.1 North America Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million) 3.9.2 Europe 3.9.2.1 Europe Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million) 3.9.3 Asia Pacific 3.9.3.1 Asia Pacific Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million) 3.9.4 Rest of the World (RoW) 3.9.4.1 Rest of the World Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million) 3.10 Competitive Landscape 3.10.1 Global Glioblastoma Treatment Market: Market Share, by Key Players 2013 (%)
Chapter 4 Global Pipeline Review of Glioblastoma Treatment 4.1 Overview 4.2 Pipeline Analysis : Types of Therapies 4.2.1 Targeted Therapy 4.2.1.1 TRC-105 4.2.2 Gene Therapy 4.2.2.1 VB-111 4.2.2.2 TOCA 511
Transparency Market Research
8
Glioblastoma Multiforme Treatment Market
4.2.3 Immunotherapy 4.2.3.1 DCVax-Brain 4.2.3.2 Rindopepimut (CDX-110) 4.2.3.3 Phase II (ACT II, ACT III and ACTIVATE) trial results of Rindopepimut 4.2.3.4 ICT-107 4.2.3.5 Trivax (AV00113) 4.3 Phase I and II Drug Entities
Chapter 5 Recommendations 5.1 Market Strategy for Success 5.1.1 Focus on the development of immunotherapy and biological therapy treatments 5.1.2 Development of novel drug delivery system (NDDS) 5.1.3 Expected intense competition in the near future
Chapter 6 Company Profiles 6.1 AbbVie, Inc. 6.1.1 Company Overview 6.1.2 Financial Overview 6.1.3 Product Portfolio 6.1.4 Business Strategies
Transparency Market Research
9
Glioblastoma Multiforme Treatment Market
6.1.4.1 Acquisitions and partnership for market penetration 6.1.5 Recent Developments 6.2 Activartis GmbH 6.2.1 Company Overview 6.2.2 Financial Overview Being a privately owned company, the financial results of Activartis Biotech GmbH is not available in the public domain. 6.2.3 Product Portfolio 6.2.4 Business Strategies 6.2.4.1 Strong focus on research and development 6.2.5 Recent Developments 6.3 Agenus Inc. 6.3.1 Company Overview 6.3.2 Financial Overview 6.3.3 Product Portfolio 6.3.4 Business Strategies 6.3.4.1 Acquisition & Merger 6.3.5 Recent Developments 6.4 Arog Pharmaceuticals, Inc. 6.4.1 Company Overview
Transparency Market Research
10
Glioblastoma Multiforme Treatment Market
6.4.2 Financial Overview 6.4.3 Product Portfolio 6.4.4 Business Strategies 6.4.4.1 Research and development 6.4.5 Acquisition of worldwide rights 6.4.6 Recent Developments 6.5 Bristol-Myers Squibb Company 6.5.1 Company Overview 6.5.2 Financial Overview 6.5.3 Product Portfolio 6.5.4 Business Strategies 6.5.4.1 Acquisitions for company’s growth 6.5.5 Recent Developments 6.6 Cavion LLC 6.6.1 Company Overview 6.6.2 Financial Overview 6.6.3 Product Portfolio 6.6.4 Business Strategies 6.6.4.1 New Drug Development 6.7 Celldex Therapeutics Inc.
Transparency Market Research
11
Glioblastoma Multiforme Treatment Market
6.7.1 Company Overview 6.7.2 Financial Overview 6.7.3 Product Portfolio 6.7.4 Business Strategies 6.7.4.1 Strong Pipeline portfolio 6.7.5 Recent Developments 6.8 CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.) 6.8.1 Company Overview 6.8.2 Financial Overview 6.8.3 Product Portfolio 6.8.4 Business Strategies 6.8.4.1 Strong Pipeline portfolio 6.8.5 Recent Developments 6.9 Cortice Biosciences Inc. 6.9.1 Company Overview 6.9.2 Financial Overview 6.9.3 Product Portfolio 6.9.4 Business Strategies 6.9.4.1 Acquisition of Exclusive Commercial Rights 6.9.5 Recent Developments
Transparency Market Research
12
Glioblastoma Multiforme Treatment Market
6.10 Eisai Co., Ltd. 6.10.1 Company Overview 6.10.2 Financial Overview 6.10.3 Product Portfolio 6.10.4 Business Strategies 6.10.4.1 Joint Research Agreement 6.10.4.2 Introduction of new lifestyle information website for breast cancer patients 6.10.5 Recent Developments 6.11 Exelixis Inc. 6.11.1 Company Overview 6.11.2 Financial Overview 6.11.3 Product Portfolio 6.11.4 Business Strategies 6.11.4.1 Strong Pipeline portfolio 6.11.4.2 Partnered compounds 6.11.5 Recent Developments 6.12 F. Hoffmann-La Roche Ltd. 6.12.1 Company Overview 6.12.2 Financial Overview 6.12.3 Product Portfolio
Transparency Market Research
13
Glioblastoma Multiforme Treatment Market
6.12.4 Business Strategies 6.12.4.1 Investment in research and development (R&D) 6.12.4.2 Strengthening core business 6.12.4.3 Mergers and Acquisitions 6.12.5 Recent Developments 6.13 Peregrine Pharmaceuticals, Inc. 6.13.1 Company Overview 6.13.2 Financial Overview 6.13.3 Product Portfolio 6.13.4 Business Strategies 6.13.4.1 Licensing agreements and collaborations 6.13.4.2 Research and development approach 6.13.5 Recent Developments 6.14 OncoSynergy 6.14.1 Company Overview 6.14.2 Financial Overview 6.14.3 Product Portfolio 6.14.4 Business Strategies 6.14.5 Recent Developments 6.15 Merrimack Pharmaceuticals, Inc.
Transparency Market Research
14
Glioblastoma Multiforme Treatment Market
6.15.1 Company Overview 6.15.2 Financial Overview 6.15.3 Product Portfolio 6.15.4 Business Strategies 6.15.4.1 Acquisition and collaboration agreement to gain market share 6.15.5 Recent Developments List of Figures
FIG. 1 Global Glioblastoma Multiforme Treatment Market, by Drug, 2013 (USD Million) FIG. 2 Comparative Analysis: Glioblastoma Multiforme Treatment Market, by Geography, 2013 and 2022 (Value %) FIG. 3 Median Overall Survival Time of Glioblastoma Patients, by Therapy FIG. 4 Global Rate of Aging Population FIG. 5 Global Glioblastoma Treatment Market: Event Impact Analysis FIG. 6 Global Bevacizumab Market Revenue, 2012 - 2022 (USD Million) FIG. 7 Global Temozolomide Market Revenue, 2012 - 2022 (USD Million) FIG. 8 Global Carmustine (BiCNU) Market Revenue, 2012 - 2022 (USD Million) FIG. 9 North America Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million) FIG. 10 Europe Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million) FIG. 11 Asia Pacific Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million)
Transparency Market Research
15
Glioblastoma Multiforme Treatment Market
FIG. 12 Rest of the World Glioblastoma Treatment Market Revenue, 2012 - 2022 (USD Million) FIG. 13 Global Glioblastoma Treatment Market: Market Share, by Key Players 2013 (%) FIG. 14 Pipeline Analysis: Glioblastoma Treatment FIG. 15 AbbVie, Inc.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 16 Agenus Inc.: Annual Revenue, 2012 – 2014 (USD Million) FIG. 17 Bristol-Myers Squibb Company: Annual Revenue, 2012 – 2014 (USD Million) FIG. 18 Eisai Co., Ltd.: Annual Revenue, 2012 – 2014 (USD Million) FIG. 19 Exelxis Inc.: Annual Revenue, 2012 – 2014 (USD Million) FIG. 20 F. Hoffmann-La Roche Ltd: Annual Revenue, 2011 – 2013 (USD Million) FIG. 21 Peregrine Pharmaceuticals, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our
Transparency Market Research
16
Glioblastoma Multiforme Treatment Market
business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/
Transparency Market Research
17